NEW YORK, NY / ACCESSWIRE/ May 31, 2018 / Pawar Law Group reminds shareholders who purchased shares of Aceto Corporation (NASDAQ: ACET) from February 1, 2018 through April 18, 2018, both dates inclusive (the “Class Period”) of the important June 25, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Aceto investors under the federal securities laws. To join the Aceto class action, go to http://pawarlawgroup.com/cases/aceto-corporation/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. You may also remain an absent class member and do nothing at this point. You may retain counsel of your choice.

According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) due to undisclosed competitive and pricing pressures, Aceto was unlikely to meet the performance metrics the Company provided to its investors as financial guidance; (2) accordingly, Aceto’s financial guidance was overstated; and (3) as a result of the foregoing, Aceto’s financial statements and defendants’ statements about Aceto’s business, operations, and prospects, were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 25, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/aceto-corporation/ to join the class action. You may also contact Vik Pawar of Pawar Law Group toll-free at 888-589-9804 or via email at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Attorney Advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
info@pawarlawgroup.com

SOURCE: Pawar Law Group

ReleaseID: 501402

NEW YORK, NY / ACCESSWIRE / May 31, 2018 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Allegiant Travel Company (“Allegiant”) (NASDAQ: ALGT) between June 8, 2015 and April 13, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Central District of California. To get more information go to:

http://www.zlk.com/pslra-d/allegiant-travel-company?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Allegiant lacked adequate systems to ensure its aircraft were being properly maintained; (2) consequently, Allegiant was not operating responsibly and ethically, and providing safe working conditions for its employees; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. On April 13, 2018, shares of Allegiant fell after news outlets reported the Company would be featured on 60 Minutes as part of an investigation of the Company’s safety and maintenance record. Then on April 15, 2018, CBS aired the report, addressing aircraft safety and maintenance issues at Allegiant. Following this news, shares of Allegiant fell from a close of $165.25 on April 12, 2018, to a close of $146.40 per share on April 16, 2018.

If you suffered a loss in Allegiant you have until June 25, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll-Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 501382

NEW YORK, NY / ACCESSWIRE / May 31, 2018 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Macquarie Infrastructure Corporation (“Macquarie”) (NYSE: MIC) between February 22, 2016 and February 21, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more information go to:

http://www.zlk.com/pslra-d/macquarie-infrastructure-corporation?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The lawsuit concerns on whether the Company and its executives violated federal securities laws by failing to disclose the shifting commodity demands and material risks facing its International-Matex Tank Terminals (“IMTT”) business segment.

On February 21, 2018, Macquarie announced it would slash its dividend and that it had lost International-Matex Tank Terminals (“IMTT”) contracts. During a conference call on February 22, 2018, CEO Christopher Frost said “a number of customers terminated contracts for a significant amount of 6 oil capacity at IMTT’s facility in St. Rose. Not only did they terminate those contracts, in some cases, they shut down their operations and exited the industry. Many of these firms have been long-term customers of IMTT.” Shares of Macquarie fell from a close of $63.62 on February 21, 2018, to a close of $37.41 on February 22, 2018.

If you suffered a loss in Macquarie you have until June 25, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll-Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 501381

NEW YORK, NY / ACCESSWIRE / May 31, 2018 / Pawar Law Group reminds shareholders who purchased shares of Myriad Genetics, Inc. (NASDAQ: MYGN) from August 13, 2014 through March 12, 2018, inclusive (“Class Period”) of the important June 19, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Myriad investors under the federal securities laws. To join the Myriad class action, go to http://pawarlawgroup.com/cases/myriad-genetics-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. You may also remain an absent class member and do nothing at this point. You may retain counsel of your choice.

According to the lawsuit, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for Myriad’s hereditary cancer testing; (2) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (3) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (4) as a result, Myriad’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 19, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/myriad-genetics-inc/ or to discuss your rights or interests regarding this class action, please contact Vik Pawar, Esq. of Pawar Law Group toll free at 888-589-9804 or via e-mail at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Attorney Advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
info@pawarlawgroup.com

SOURCE: Pawar Law Group

ReleaseID: 501400

NEW YORK, NY / ACCESSWIRE / May 31, 2018 / Pawar Law Group reminds shareholders who purchased shares of Longfin Corp. (NASDAQ: LFIN) between December 13, 2017 and April 2, 2018, both dates inclusive (“Class Period”) of the important June 4, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Longfin investors under the federal securities laws. To join the Longfin class action, go to http://pawarlawgroup.com/cases/longfin-corp/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. You may also remain an absent class member and do nothing at this point. You may retain counsel of your choice.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Longfin included several false statements in its SEC filings in connection with its IPO which prompted an SEC investigation, including wrongly representing Defendant Meenavalli’s age, location of Longfin’s principal offices, and listing Sarah Altahawi as an officer when she did not have that position; (2) Longfin acquired Ziddu.com shortly after the IPO to capitalize on the popularly of blockchain companies in order to manipulate the Company’s stock price; (3) Longfin’s acquisition of Ziddu.com prompted an SEC investigation; (4) Longfin knew that it was ineligible to be listed on the Russell 2000 and 3000 indices; and (5) as a result of the foregoing, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 4, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/longfin-corp/ to join the class action. You may also contact Vik Pawar of Pawar Law Group toll free at 888-589-9804 or via email at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
info@pawarlawgroup.com

SOURCE: Pawar Law Group

ReleaseID: 501399

NEW YORK, NY / ACCESSWIRE / May 31, 2018 / Pawar Law Group reminds shareholders who purchased shares of the American Depository Shares of Micro Focus International plc (NYSE: MFGP) pursuant or traceable to the Micro Focus’s Registration Statement and Prospectus issued in connection with the merger of Micro Focus with Hewlett Packard Enterprise Company (“HPE”), and their subsidiaries that closed on September 1, 2017 (the “Merger”) of the important July 23, 2018 lead plaintiff deadline in the class action. To join the Micro Focus class action, go to http://pawarlawgroup.com/cases/micro-focus-international-plc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. You may also remain an absent class member and do nothing at this point. You may retain counsel of your choice.

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) HPE Software was experiencing significant disruptions in global customer accounts from its de-merger from HP; (2) HPE Software and Micro Focus were experiencing employee attrition, which adversely impacted Micro Focus’s operational capabilities and revenue trends; (3) Micro Focus was suffering worsening revenue trends and on pace to significantly miss market expectations for its interim results in its core legacy business for the six months ended October 31, 2017; (4) Micro Focus was experiencing significant sales execution problems in its North America region; (5) HPE Software did not have the operational capabilities, loyal customer base, products or key personnel to justify its purchase price or to reverse worsening revenue trends; (6) Micro Focus had failed to put in place the operations, procedures and personnel necessary to integrate successfully with HPE Software to provide a reasonable likelihood that the purported synergies from the Merger would be realized; (7) the total enterprise value for the Merger was artificially inflated by more than $3.4 billion; and (8) as a result Micro Focus’s ability to service the increased debt load it had incurred as a result of the Merger had been materially impaired. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 23, 2018. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/micro-focus-international-plc/ to join the class action. You may also contact Vik Pawar of Pawar Law Group toll-free at 888-589-9804 or via email at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Attorney Advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
info@pawarlawgroup.com

SOURCE: Pawar Law Group

ReleaseID: 501407

NEW YORK, NY / ACCESSWIRE / May 31, 2018 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Esperion Therapeutics, Inc. (“Esperion”) (NASDAQ: ESPR) between February 22, 2017 and May 1, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of Michigan. To get more information go to:

http://www.zlk.com/pslra-d/esperion-therapeutics?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Esperion’s cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death; and (ii) as a result of the foregoing, Esperion’s public statements were materially false and misleading at all relevant times. On May 2, 2018, Esperion announced results from its second Phase 3 study for its cholesterol-lowering medication bempedoic acid. Esperion reported that while the trial met the primary endpoint of safety and tolerability and the key efficacy endpoint, there were 13 deaths in the treatment group compared to only two in the control group. On this news, Esperion’s share price fell from a close of $70.50 per share on May 1, 2018, to a close of $45.75 per share the following day.

If you suffered a loss in Esperion you have until July 6, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 501388

NEW YORK, NY / ACCESSWIRE / May 31, 2018 / Pawar Law Group reminds shareholders who purchased shares of Edge Therapeutics, Inc. (NASDAQ: EDGE) from December 29, 2017 through March 27, 2018, both dates inclusive (the “Class Period”) of the important June 22, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Edge Therapeutics investors under the federal securities laws. To join the Edge Therapeutics class action, go to http://pawarlawgroup.com/cases/edge-therapeutics-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. You may also remain an absent class member and do nothing at this point. You may retain counsel of your choice.

According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) the company’s lead product candidate, EG-1962, would likely fail a futility analysis in connection with the NEWTON 2 study; and (2) as a result, Edge Therapeutics’ financial statements and defendants’ statements about the company’s business, operations, and prospects, were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 22, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/edge-therapeutics-inc/ to join the class action. You may also contact Vik Pawar of Pawar Law Group toll-free at 888-589-9804 or via email at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Attorney Advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
info@pawarlawgroup.com

SOURCE: Pawar Law Group

ReleaseID: 501404

PORT VILA, VANUATU / ACCESSWIRE / May 31, 2018 / Algorithm trading is a very advanced and sophisticated investing mechanism which uses complex mathematical formulas and models to make quick decisions and transactions in financial markets. According to a recent study from FinTech research company Technavio, algorithm trading is expected to continue growing at a global annual rate of 10.3 percent through the year 2020. Emporio Trading, an industry-leading online Forex brokerage firm, explains why traditional investment institutions are building tech-savvy algorithm platforms to help improve market intelligence and long-term trade decisions.

The expert panelists from Emporio Trading explained that there are various algorithm trading strategies being implemented by both large firms and institutional brokers today. However, nearly all of these advanced solutions have the same focus — to predict future stock prices by using past trading analysis. Recent studies conducted by Nature Scientific Reports indicated that even Google and Wikipedia searches can be used in algorithms to assist during the information gathering phase. Weekly and monthly search averages for a particular term (e.g. Loans by Private Banks) can be measured to buy, hold, sell or re-buy stocks for that period. Algo (algorithm) traders are also using the mean reversion theory, which states that the prices of stocks converge to their average value over time, to execute orders automatically if a price moves out of a defined range. While selling high performing stocks and buying low performing ones is a simple, widely-used strategy, having the technology to set strict parameters and carry out orders autonomously removes almost all legwork for the investor.

Essentially, these computer-directed trading models turn pieces of information into intelligent trading decisions by analyzing every quote and trade in the stock market and identifying liquidity opportunities. Because algorithms are written in advance, their functions are executed automatically as and when required, without any user guidance. As such, Algo traders generally enjoy three benefits over the traditional investor – speed, accuracy and lower cost. Algorithms can execute on multiple indicators simultaneously, so orders are carried out in a fraction of a second, removing the chance of human error and making greater opportunities available at better prices. For example, in the Forex market, changes in exchange rates can be continuously monitored 24/7 and acted upon immediately if necessary without any user intervention. Traders do not have to follow up on their stocks frequently, allowing them more time to explore and focus on other investment opportunities. Most importantly, Algo trading mitigates risk and ensures security for investors. Algorithms prevent information leakage for those who do not wish to share quotes; in addition, they calculate risks continuously and accordingly hedge a position in the market, leading to minimum losses.

Headquartered in the Republic of Vanuatu, Emporio Trading is a globally recognized Forex Company that offers the industry’s most competitive pricing, reliable trade execution, and innovative trading tools. Today, Emporio Trading is a comprehensive trading center with five types of instruments to trade 48 currency pairs, metals, indices share, and cryptocurrencies.

EmporioTrading.com – Worldwide Forex Market Leader: http://emporiotradingnews.com

Emporio Trading – Explores the Role of Institutional Investors in Currency Trading: https://finance.yahoo.com/news/emporio-trading-explores-role-institutional-141000106.html

Emporio Trading – Analyzes Factors Affecting Commodities Markets: https://finance.yahoo.com/news/emporio-trading-analyzes-factors-affecting-040000525.html

Contact Information:

EmporioTradingNews.com
contact@emporiotradingnews.com
http://emporiotradingnews.com

SOURCE: EmporioTrading.com

ReleaseID: 501409

NEW YORK, NY / ACCESSWIRE / May 31, 2018 / Pawar Law Group reminds shareholders who purchased shares of QuinStreet, Inc. (NASDAQ: QNST) from February 10, 2016 through April 10, 2018, both dates inclusive (“Class Period”) of the important June 26, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for QuinStreet investors under the federal securities laws. To join the QuinStreet class action, go to http://pawarlawgroup.com/cases/quinstreet-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. You may also remain an absent class member and do nothing at this point. You may retain counsel of your choice.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) QuinStreet recklessly disregarded the occurrence of click-through fraud; (2) QuinStreet-owned websites experienced phony, low-quality traffic for its clients; (3) QuinStreet’s practices were not geared toward providing its clients with valuable customers or high-quality leads or clicks; and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 26, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/quinstreet-inc/ to join the class action. You may also contact Vik Pawar of Pawar Law Group toll-free at 888-589-9804 or via email at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Attorney Advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
info@pawarlawgroup.com

SOURCE: Pawar Law Group

ReleaseID: 501405